New Parkinson's Drug

New Parkinson's Drug Approved

— Treatment improves "off" time when used as add-on

by Judy George, Senior Staff Writer, MedPage Today August 28, 2019

SILVER SPRING, Md. – The FDA approved istradefylline (Nourianz) as an add-on treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing "off" episodes, the agency announced late Tuesday.

Istradefylline is an orally administered, selective adenosine A_2Areceptor antagonist and has been marketed in Japan since 2013 as adjunctive treatment to levodopa-containing products for Parkinson's patients.